Search

Your search keyword '"Mariette, C"' showing total 1,151 results
Start Over Author "Mariette, C"
1,151 results on '"Mariette, C"'

59. Cancer du pancréas localement évolué non resécable : chimioradiothérapie d’induction suivie de chimiothérapie par gemcitabine contre chimiothérapie exclusive par gemcitabine : résultats définitifs de l’étude de phase III 2000–2001de la FFCD et de la SFRO

Author

Barhoumi, M., Mornex, F., Bonnetain, F., Rougier, P., Mariette, C., Bouché, O., Bosset, J.-F., Aparicio, T., Mineur, L., Azzedine, A., Hammel, P., Butel, J., Stremsdoerfer, N., Maingon, P., Bedenne, L., and Chauffert, B.

Published
2011
Full Text
View/download PDF

77. LBA-04 The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results

Author

Bennouna, J., Etienne, P.-L., Bogart, E., Galais, M.-P., Benabdelghani, M., Francois, E., Michel, P., Dahan, L., Metges, J.-P., Ghiringhelli, F., Conroy, T., Kotecki, N., Bedenne, L., El Hajbi, F., Samalin, E., Piessen, G., Delaine-Clisant, S., Penel, N., Mariette, C., and Adenis, A.

Published
2016
Full Text
View/download PDF

79. Patient-reported outcomes after oesophagectomy in the multicentre LASER study

Author

Markar, S R, primary, Sounderajah, V, additional, Johar, A, additional, Zaninotto, G, additional, Castoro, C, additional, Lagergren, P, additional, Elliott, J A, additional, Gisbertz, S S, additional, Mariette, C, additional, Alfieri, R, additional, Huddy, J, additional, Pinto, E, additional, Scarpa, M, additional, Klevebro, F, additional, Sunde, B, additional, Murphy, C F, additional, Greene, C, additional, Ravi, N, additional, Piessen, G, additional, Brenkman, H, additional, Ruurda, J, additional, van Hillegersberg, R, additional, Lagarde, S M, additional, Wijnhoven, B P, additional, Pera, M, additional, Roigg, J, additional, Castro, S, additional, Matthijsen, R, additional, Findlay, J, additional, Antonowicz, S, additional, Maynard, N, additional, McCormack, O, additional, Ariyarathenam, A, additional, Sanders, G, additional, Cheong, E, additional, Jaunoo, S, additional, Allum, W, additional, van Lanschot, J, additional, Nilsson, M, additional, Reynolds, J V, additional, van Berge Henegouwen, M I, additional, and Hanna, G B, additional

Published
2021
Full Text
View/download PDF

80. Patient-reported outcomes after oesophagectomy in the multicentre LASER study

Author

Markar, S. R., Sounderajah, V., Johar, A., Zaninotto, G., Castoro, C., Lagergren, P., Elliott, J. A., Gisbertz, S. S., Mariette, C., Alfieri, R., Huddy, J., Pinto, E., Scarpa, M., Klevebro, F., Sunde, B., Murphy, C. F., Greene, C., Ravi, N., Piessen, G., Brenkman, H., Ruurda, J., van Hillegersberg, R., Lagarde, S. M., Wijnhoven, B. P., Pera, M., Roigg, J., Castro, S., Matthijsen, R., Findlay, J., Antonowicz, S., Maynard, N., McCormack, O., Ariyarathenam, A., Sanders, G., Cheong, E., Jaunoo, S., Allum, W., van Lanschot, J., Nilsson, M., Reynolds, J. V., van Berge Henegouwen, M. I., Hanna, G. B., Markar, S. R., Sounderajah, V., Johar, A., Zaninotto, G., Castoro, C., Lagergren, P., Elliott, J. A., Gisbertz, S. S., Mariette, C., Alfieri, R., Huddy, J., Pinto, E., Scarpa, M., Klevebro, F., Sunde, B., Murphy, C. F., Greene, C., Ravi, N., Piessen, G., Brenkman, H., Ruurda, J., van Hillegersberg, R., Lagarde, S. M., Wijnhoven, B. P., Pera, M., Roigg, J., Castro, S., Matthijsen, R., Findlay, J., Antonowicz, S., Maynard, N., McCormack, O., Ariyarathenam, A., Sanders, G., Cheong, E., Jaunoo, S., Allum, W., van Lanschot, J., Nilsson, M., Reynolds, J. V., van Berge Henegouwen, M. I., and Hanna, G. B.

Abstract

BACKGROUND: Data on the long-term symptom burden in patients surviving oesophageal cancer surgery are scarce. The aim of this study was to identify the most prevalent symptoms and their interactions with health-related quality of life. METHODS: This was a cross-sectional cohort study of patients who underwent oesophageal cancer surgery in 20 European centres between 2010 and 2016. Patients had to be disease-free for at least 1 year. They were asked to complete a 28-symptom questionnaire at a single time point, at least 1 year after surgery. Principal component analysis was used to assess for clustering and association of symptoms. Risk factors associated with the development of severe symptoms were identified by multivariable logistic regression models. RESULTS: Of 1081 invited patients, 876 (81.0 per cent) responded. Symptoms in the preceding 6 months associated with previous surgery were experienced by 586 patients (66.9 per cent). The most common severe symptoms included reduced energy or activity tolerance (30.7 per cent), feeling of early fullness after eating (30.0 per cent), tiredness (28.7 per cent), and heartburn/acid or bile regurgitation (19.6 per cent). Clustering analysis showed that symptoms clustered into six domains: lethargy, musculoskeletal pain, dumping, lower gastrointestinal symptoms, regurgitation/reflux, and swallowing/conduit problems; the latter two were the most closely associated. Surgical approach, neoadjuvant therapy, patient age, and sex were factors associated with severe symptoms. CONCLUSION: A long-term symptom burden is common after oesophageal cancer surgery.

Published
2021

81. Patient-reported outcomes after oesophagectomy in the multicentre LASER study

Author

MS CGO, Cancer, Markar, S R, Sounderajah, V, Johar, A, Zaninotto, G, Castoro, C, Lagergren, P, Elliott, J A, Gisbertz, S S, Mariette, C, Alfieri, R, Huddy, J, Pinto, E, Scarpa, M, Klevebro, F, Sunde, B, Murphy, C F, Greene, C, Ravi, N, Piessen, G, Brenkman, H, Ruurda, J, van Hillegersberg, R, Lagarde, S M, Wijnhoven, B P, Pera, M, Roigg, J, Castro, S, Matthijsen, R, Findlay, J, Antonowicz, S, Maynard, N, McCormack, O, Ariyarathenam, A, Sanders, G, Cheong, E, Jaunoo, S, Allum, W, van Lanschot, J, Nilsson, M, Reynolds, J V, van Berge Henegouwen, M I, Hanna, G B, MS CGO, Cancer, Markar, S R, Sounderajah, V, Johar, A, Zaninotto, G, Castoro, C, Lagergren, P, Elliott, J A, Gisbertz, S S, Mariette, C, Alfieri, R, Huddy, J, Pinto, E, Scarpa, M, Klevebro, F, Sunde, B, Murphy, C F, Greene, C, Ravi, N, Piessen, G, Brenkman, H, Ruurda, J, van Hillegersberg, R, Lagarde, S M, Wijnhoven, B P, Pera, M, Roigg, J, Castro, S, Matthijsen, R, Findlay, J, Antonowicz, S, Maynard, N, McCormack, O, Ariyarathenam, A, Sanders, G, Cheong, E, Jaunoo, S, Allum, W, van Lanschot, J, Nilsson, M, Reynolds, J V, van Berge Henegouwen, M I, and Hanna, G B

Published
2021

82. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study

Author

Chauffert, B., Mornex, F., Bonnetain, F., Rougier, P., Mariette, C., Bouché, O., Bosset, J.F., Aparicio, T., Mineur, L., Azzedine, A., Hammel, P., Butel, J., Stremsdoerfer, N., Maingon, P., and Bedenne, L.

Published
2008
Full Text
View/download PDF

86. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Author

Richardson, Paul G, Oriol, Albert, Beksac, Meral, Liberati, Anna Marina, Galli, Monica, Schjesvold, Fredrik, Lindsay, Jindriska, Weisel, Katja, White, Darrell, Facon, Thierry, San Miguel, Jesus, Sunami, Kazutaka, O'Gorman, Peter, Sonneveld, Pieter, Robak, Pawel, Semochkin, Sergey, Schey, Steve, Yu, Xin, Doerr, Thomas, Bensmaine, Amine, Biyukov, Tsvetan, Peluso, Teresa, Zaki, Mohamed, Anderson, Kenneth, Dimopoulos, Meletios, OPTIMISMM trial investigators, Abildgaard N, Adler H, Altuntas F, Akay OM, Amin B, Anagnostopoulos A, Anderson L, Anttila P, Araujo C, Arce-Lara C, Aydin Y, Basu S, Battini R, Beeker T, Benboubker L, Ben-Yehuda D, Bladé J, Blau IW, Boccia R, Burke L, Byeff P, Cascavilla N, Cavo M, Chantry A, Charles Y, Chaudhry A, Corso A, Coyne M, De Arriba F, Delimpasi S, Desjardins P, Dhakal B, Di Bartolomeo P, Di Raimondo F, Dürig J, Engelhardt M, Escoffre-Barbe M, Esteves G, Flogegard M, Gabrail N, Gamberi B, Garrison M, Gay J, Gisslinger H, Goldschmidt H, Goncalves C, Gressot L, Grosicki S, Hanna W, Hayden P, Henriques Bernardo MM, Hermann R, Holden V, Honkalehto K, Huben M, Huffman J, Hunter H, Hus M, Jagasia M, Jagganath S, Janakiram M, Jaiyesimi I, Jenner M, João C, Johnson P, Jurcyszyn A, Kalayoğlu Beşişik S, Kambhampati S, Kanate A, Karadoğan I, Khojasteh A, Kirkel D, Komarnicki M, Krauth MT, Kuriakose P, Larocca A, Lauri B, Leleu X, Lucio P, Luppi M, Mangiacavalli S, Mariette C, Matsue K, Mellqvist UH, Mendeleeva L, Meshad M, Miller C, Mohrbacher A, Moreau P, Morelli AM, Müldür E, Naassan A, Nahi H, Nair R, O'Dwyer M, Öngören Aydin S, Openshaw T, O'Rourke T, Osswald M, Overton L, Pati A, Pavic M, Pegourie B, Pehlivan M, Pierola AA, Plesner T, Pluta A, Rabin N, Ramasamy K, Rambaldi A, Rodriguez P, Röllig C, Rosenblatt J, Rosenbluth J, Salomo M, Samoylova O, Sastre Moral J, Sati H, Selleri C, Shafeek S, Shinagawa A, Sleckman B, Smith C, Sonmez M, Stone C, Streetly M, Suzuki K, Taetle R, Tafuri A, Takezako N, Teke HÜ, Vapaatalo M, Vassilopoulos G, Verma A, Vidito S, Viterbo L, Vural F, Wang XS, Yağci M, Yee A., Richardson, Paul G, Oriol, Albert, Beksac, Meral, Liberati, Anna Marina, Galli, Monica, Schjesvold, Fredrik, Lindsay, Jindriska, Weisel, Katja, White, Darrell, Facon, Thierry, San Miguel, Jesu, Sunami, Kazutaka, O'Gorman, Peter, Sonneveld, Pieter, Robak, Pawel, Semochkin, Sergey, Schey, Steve, Yu, Xin, Doerr, Thoma, Bensmaine, Amine, Biyukov, Tsvetan, Peluso, Teresa, Zaki, Mohamed, Anderson, Kenneth, Dimopoulos, Meletio, OPTIMISMM trial investigator, Abildgaard N, Adler H, Altuntas F, Akay OM, Amin B, Anagnostopoulos A, Anderson L, Anttila P, Araujo C, Arce-Lara C, Aydin Y, Basu S, Battini R, Beeker T, Benboubker L, Ben-Yehuda D, Bladé J, Blau IW, Boccia R, Burke L, Byeff P, Cascavilla N, Cavo M, Chantry A, Charles Y, Chaudhry A, Corso A, Coyne M, De Arriba F, Delimpasi S, Desjardins P, Dhakal B, Di Bartolomeo P, Di Raimondo F, Dürig J, Engelhardt M, Escoffre-Barbe M, Esteves G, Flogegard M, Gabrail N, Gamberi B, Garrison M, Gay J, Gisslinger H, Goldschmidt H, Goncalves C, Gressot L, Grosicki S, Hanna W, Hayden P, Henriques Bernardo MM, Hermann R, Holden V, Honkalehto K, Huben M, Huffman J, Hunter H, Hus M, Jagasia M, Jagganath S, Janakiram M, Jaiyesimi I, Jenner M, João C, Johnson P, Jurcyszyn A, Kalayoğlu Beşişik S, Kambhampati S, Kanate A, Karadoğan I, Khojasteh A, Kirkel D, Komarnicki M, Krauth MT, Kuriakose P, Larocca A, Lauri B, Leleu X, Lucio P, Luppi M, Mangiacavalli S, Mariette C, Matsue K, Mellqvist UH, Mendeleeva L, Meshad M, Miller C, Mohrbacher A, Moreau P, Morelli AM, Müldür E, Naassan A, Nahi H, Nair R, O'Dwyer M, Öngören Aydin S, Openshaw T, O'Rourke T, Osswald M, Overton L, Pati A, Pavic M, Pegourie B, Pehlivan M, Pierola AA, Plesner T, Pluta A, Rabin N, Ramasamy K, Rambaldi A, Rodriguez P, Röllig C, Rosenblatt J, Rosenbluth J, Salomo M, Samoylova O, Sastre Moral J, Sati H, Selleri C, Shafeek S, Shinagawa A, Sleckman B, Smith C, Sonmez M, Stone C, Streetly M, Suzuki K, Taetle R, Tafuri A, Takezako N, Teke HÜ, Vapaatalo M, Vassilopoulos G, Verma A, Vidito S, Viterbo L, Vural F, Wang XS, Yağci M, Yee A., and Hematology

Subjects
Oncology, Adult, Male, medicine.medical_specialty, Adolescent, Population, Dexamethasone, Bortezomib, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Internal medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, education, Survival rate, Lenalidomide, Multiple myeloma, Aged, Salvage Therapy, education.field_of_study, business.industry, Pomalidomide, bortezomib, dexamethasone, Middle Aged, Pomalidomide, medicine.disease, Prognosis, Thalidomide, Survival Rate, Regimen, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business, Multiple Myeloma, 030215 immunology, medicine.drug, Follow-Up Studies
Abstract

Background As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has shown promising results in phase 1/2 trials of patients with relapsed or refractory multiple myeloma. We aimed to assess the efficacy and safety of this triplet regimen in patients with relapsed or refractory multiple myeloma who previously received lenalidomide. Methods We did a randomised, open-label, phase 3 trial at 133 hospitals and research centres in 21 countries. We enrolled patients (aged >= 18 years) with a diagnosis of multiple myeloma and measurable disease, an Eastern Cooperative Oncology Group performance status of 0-2, who received one to three previous regimens, including a lenalidomide-containing regimen for at least two consecutive cycles. We randomly assigned patients (1:1) to bortezomib and dexamethasone with or without pomalidomide using a permutated blocked design in blocks of four, stratified according to age, number of previous regimens, and concentration of beta(2) microglobulin at screening. Bortezomib (1.3 mg/m(2)) was administered intravenously until protocol amendment 1 then either intravenously or subcutaneously on days 1,4, 8, and 11 for the first eight cycles and subsequently on days 1 and 8. Dexamethasone (20 mg [10 mg if age >75 years]) was administered orally on the same days as bortezomib and the day after. Patients allocated pomalidomide received 4 mg orally on days 1-14. Treatment cycles were every 21 days. The primary endpoint was progression-free survival in the intention-to-treat population, as assessed by an independent review committee. Safety was assessed in all patients who received at least one dose of study medication. This trial is registered at ClinicalTrials.gov, number NCT01734928; patients are no longer being enrolled. Findings Between Jan 7, 2013, and May 15,2017,559 patients were enrolled. 281 patients were assigned pomalidomide, bortezomib, and dexamethasone and 278 were allocated bortezomib and dexamethasone. Median follow-up was 15.9 months (IQR 9.9-21.7). Pomalidomide, bortezomib, and dexamethasone significantly improved progression-free survival compared with bortezomib and dexamethasone (median 11.20 months [95% CI 9.66-13-73] vs 7.10 months [5.88-8-48]; hazard ratio 0.61, 95% CI 0.49-0-77; p

Published
2019

88. Functional outcomes in symptomatic versus asymptomatic patients undergoing incisional hernia repair: Replacing one problem with another? A prospective cohort study in 1312 patients

Author

Smet, G.H.J. de, Sneiders, D. (Dimitri), Yurtkap, Y. (Yağmur), Menon, A.G. (Anand), Jeekel, J. (Hans), Kleinrensink, G.J. (Gert Jan), Lange, J.F. (Johan), Gillion, J.-F. (Jean-François), Abet, E. (E.), Ain, J.-F. (J. F.), Arnalsteen, L. (L.), Baraket, O. (O.), Beck, M. (M.), Bellouard, A. (A.), Benizri, E. (E.), Berney, C. (C.), Bilem, D. (D.), Binot, D. (D.), Blanc, B. (B.), Blazquez, D. (D.), Bonan, A. (A.), Boukortt, T. (T.), Brehant, O. (O.), Cas, O. (O.), Champault-Fezais, A. (A.), Chau, A. (A.), Chollet, J.-M. (J. M.), Constantin, M. (M.), Cossa, J.-P. (J. P.), Dabrowski, A. (A.), David, A. (A.), Demaret, S. (S.), Dubuisson, V. (V.), Dugue, T. (T.), El Nakadi, I., Faure, J.-P. (J. P.), Frileux, P. (P.), Fromont, G. (G.), Gadiri, N. (N.), Gillion, J.F. (Jean-Francois), Glehen, O. (O.), Hennequin, S. (S.), Isambert, M. (M.), Jurczak, F. (F.), Khalil, H. (H.), Lamblin, A. (A.), Largenton, C. (C.), Lavy, M. (M.), Lepère, M. (M.), Le Toux, N. (N.), Magne, E. (E.), Manfredelli, S. (S.), Mariette, C. (Christophe), Marion, Y. (Y.), Mercoli, H.-A. (H. A.), Mesli Smain, N. (N.), Moszkowicz, D. (D.), Najim, M. (M.), Oberlin, O. (O.), Odet, E. (E.), Ortega Deballon, P. (P.), Pavis d'Escurac, X. (X.), Pichot Delahaye, V. (V.), Putinier, J.B. (J. B.), Regimbeau, J.M. (J. M.), Renard, Y. (Y.), Romain, B. (B.), Rouquie, D. (D.), Soler, M. (M.), Soufron, J. (J.), Roos, S. (S.), Thillois, J.-M. (J. M.), Tiry, P. (P.), Vauchaussade De Chaumont, A. (A.), Vinatier, E. (E.), Vu, P. (P.), Verhaeghe, R. (R.), Zaranis, C. (C.), Zeineb, M. (M.), Smet, G.H.J. de, Sneiders, D. (Dimitri), Yurtkap, Y. (Yağmur), Menon, A.G. (Anand), Jeekel, J. (Hans), Kleinrensink, G.J. (Gert Jan), Lange, J.F. (Johan), Gillion, J.-F. (Jean-François), Abet, E. (E.), Ain, J.-F. (J. F.), Arnalsteen, L. (L.), Baraket, O. (O.), Beck, M. (M.), Bellouard, A. (A.), Benizri, E. (E.), Berney, C. (C.), Bilem, D. (D.), Binot, D. (D.), Blanc, B. (B.), Blazquez, D. (D.), Bonan, A. (A.), Boukortt, T. (T.), Brehant, O. (O.), Cas, O. (O.), Champault-Fezais, A. (A.), Chau, A. (A.), Chollet, J.-M. (J. M.), Constantin, M. (M.), Cossa, J.-P. (J. P.), Dabrowski, A. (A.), David, A. (A.), Demaret, S. (S.), Dubuisson, V. (V.), Dugue, T. (T.), El Nakadi, I., Faure, J.-P. (J. P.), Frileux, P. (P.), Fromont, G. (G.), Gadiri, N. (N.), Gillion, J.F. (Jean-Francois), Glehen, O. (O.), Hennequin, S. (S.), Isambert, M. (M.), Jurczak, F. (F.), Khalil, H. (H.), Lamblin, A. (A.), Largenton, C. (C.), Lavy, M. (M.), Lepère, M. (M.), Le Toux, N. (N.), Magne, E. (E.), Manfredelli, S. (S.), Mariette, C. (Christophe), Marion, Y. (Y.), Mercoli, H.-A. (H. A.), Mesli Smain, N. (N.), Moszkowicz, D. (D.), Najim, M. (M.), Oberlin, O. (O.), Odet, E. (E.), Ortega Deballon, P. (P.), Pavis d'Escurac, X. (X.), Pichot Delahaye, V. (V.), Putinier, J.B. (J. B.), Regimbeau, J.M. (J. M.), Renard, Y. (Y.), Romain, B. (B.), Rouquie, D. (D.), Soler, M. (M.), Soufron, J. (J.), Roos, S. (S.), Thillois, J.-M. (J. M.), Tiry, P. (P.), Vauchaussade De Chaumont, A. (A.), Vinatier, E. (E.), Vu, P. (P.), Verhaeghe, R. (R.), Zaranis, C. (C.), and Zeineb, M. (M.)

Abstract

Background: Incisional hernias can be associated with pain or discomfort. Surgical repair especially mesh reinforcement, may likewise induce pain. The primary objective was to assess the incidence of pain after hernia repair in patients with and without pre-operative pain or discomfort. The secondary objectives were to determine the preferred mesh type, mesh location and surgical technique in minimizing postoperative pain or discomfort. Materials and methods: A registry-based prospective cohort study was performed, including patients undergoing incisional hernia repair between September 2011 and May 2019. Patients with a minimum follow-up of 3–6 months were included. The incidence of hernia related pain and discomfort was recorded perioperatively. Results: A total of 1312 patients were included. Pre-operatively, 1091 (83%) patients reported pain or discomfort. After hernia repair, 961 (73%) patients did not report pain or discomfort (mean follow-up = 11.1 months). Of the pre-operative asymptomatic patients (n = 221), 44 (20%, moderate or severe pain: n = 14, 32%) reported pain or discomfort after mean follow-up of 10.5 months. Of those patients initially reporting pain or discomfort (n = 1091), 307 (28%, moderate or severe pain: n = 80, 26%) still reported pain or discomfort after a mean follow-up of 11.3 months postoperatively. Conclusion: In symptomatic incisional hernia patients, hernia related complaints may be resolved in the majority of cases undergoing surgical repair. In asymptomatic incisional hernia patients, pain or discomfort may be induced in a considerable number of patients due to surgical repair and one should be aware if this postoperative complication.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results